LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

Summary

This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with CRPC.

Timeline

Start

2020-07-16

Primary completion

2022-05-15

Completion

2024-10-15

Outcome

Outcome not reported

Stopped: “Due to efficacy evaluation”

Drugs

Indications